TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01181622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denufosol tetrasodium Inhalation Solution
Description: 60 mg by oral inhalation three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% w/v sodium chloride solution
Description: 0.9% w/v sodium chloride solution by oral inhalation three times daily
Study: NCT01199718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
Study: NCT00863083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifamily weight management intervention
Description: 8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
Study: NCT03681223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic assisted laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
Study: NCT01503671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40 mg/day
Study: NCT01411553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disposable ECG-LW
Description: Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
Study: NCT01922401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inverse ratio ventilation
Description: change the I: E ratio 1:2-1:1-2:1
Study: NCT00721253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis
Description: Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acri.LISA
Description: Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
Study: NCT04309799

Intervention type: DEVICE
Group type: OTHER
Intervention: Tear Restore Mask
Description: The Tear Restore Mask will be used for 10 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: Tear Restore Mask
Description: The Tear Restore Mask will be used for 10 minutes
Study: NCT01114230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV
Study: NCT01238588

Intervention type: DRUG
Group type: OTHER
Intervention: Sevelamer Carbonate (Renvela)
Description: Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
Study: NCT02229656

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
Study: NCT03289520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03367247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOLSTER
Description: BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
Study: NCT03367247

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Discharge Planning (EDP)
Description: EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
Study: NCT02635646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family and interdisciplinary approach
Description: Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual approach
Description: individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually.
Study: NCT03011892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 0.15% Cream QD
Description: Ruxolitinib 0.15% cream QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 0.5% Cream QD
Description: Ruxolitinib 0.5% cream QD
Study: NCT01746329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Oral intake of tea containing 75 grams of glucose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beet root
Description: Oral intake of beetroot juice containing 75 grams of glucose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of 75 grams of glucose in water
Study: NCT01903161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed remote ischemic preconditioning
Description: In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
Study: NCT02449265

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation involved-site radiotherapy (ISRT)
Description: 6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation involved-field radiotherapy (IFRT)
Description: 6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15\~18 fractions of 2 Gy 5 days per week for partial response (PR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Patients in both arms will be given cyclophpsphamide chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients in both arms will be given cyclophpsphamide chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Patients in both arms will be given doxorubicin chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Patients in both arms will be given doxorubicin chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: Patients in both arms will be given vincristine chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Patients in both arms will be given vincristine chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Patients in both arms will be given prednisone chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Patients in both arms will be given prednisone chemotherapy.
Study: NCT01597245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab Dosing Regimen
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab Dosing Regimen
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab Dosing Regimen
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg etanercept
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03749512

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: During routine preoperative blood test complete blood count is taken.

Intervention type: OTHER
Intervention: Histopathological examination
Description: Routine postoperative histopathological examination of lung tumor.
Study: NCT04459585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate Mesylate
Description: Single oral 150 mg capsule dose
Study: NCT01909102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study: NCT04459585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
Study: NCT01229618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C) injection
Description: single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Study: NCT03053674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaire
Description: Follow-up questionnaire to determine whether participants have receive post-partum vaccination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up questionnaire
Description: Follow-up questionnaire to determine whether participants have receive post-partum vaccination
Study: NCT01868074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Custom-molded arch-supporting insole
Study: NCT01229618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C) injection
Description: single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C) injection
Description: single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Study: NCT01794715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound examination by nurses
Description: Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by nurses
Description: Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
Study: NCT00612287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
Study: NCT00704691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
Study: NCT01650350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study.
Study: NCT03858777

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured
Study: NCT02241434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Intrathecal autologous bone marrow mononuclear cell transplantation
Study: NCT01940341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: Tablet administered orally once daily
Study: NCT03459807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Hypertensive medications
Description: Use of standard Anti-Hypertensive medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Hypertensive medications
Description: Use of standard Anti-Hypertensive medications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Weight Adjustment
Description: The participant's target post-dialysis dry weight is adjusted

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Weight Adjustment
Description: The participant's target post-dialysis dry weight is adjusted
Study: NCT03552393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mircera
Description: The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
Study: NCT02009163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once per day (double-blind period)
Study: NCT03081403

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative Sensory Testing
Description: Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.

Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative Sensory Testing
Description: Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
Study: NCT03011892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream QD
Description: Ruxolitinib 1.5% cream QD
Study: NCT03143335

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retropectoral immediate breast reconstruction
Description: Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prepectoral immediate breast reconstruction
Description: Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
Study: NCT03509376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture repair
Description: The diastasis is repaired with continous nylon suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rolled mesh repair
Description: Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
Study: NCT04262102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SD_SF
Description: Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SD_BLW
Description: Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HFV_SF
Description: Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HFV_BLW
Description: Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
Study: NCT05592535

Intervention type: PROCEDURE
Intervention: Coronary revascularization
Description: Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
Study: NCT03561727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mass closure technique
Description: Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Layered closure technique
Description: he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
Study: NCT00652288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin analogs (Lispro and Aspart)
Description: Insulin bolus given through insulin pump
Study: NCT04024787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural therapy for insomnia (CBT-I)
Description: Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.~One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks.
Study: NCT04430296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophotocoagulation
Description: High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye.
Study: NCT03904680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 2.5 mg tablet
Study: NCT00652288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin analogs (Lispro and Aspart)
Description: Insulin bolus given through insulin pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin analogs (Aspart and Detemir)
Description: Drugs given separately
Study: NCT03570593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY
Description: Removal of urinary catheter on the first day after radical surgery
Study: NCT04575012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred invasive strategy
Description: PCI on 7 to 10 days after symptom onset

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early invasive strategy
Description: Primary PCI
Study: NCT03594552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_15
Description: Single oral dose (15mg)